Gilead Sciences
Company
FilterAll
Business
Culture
Environment
Health
Politics
Research
Key facts
- City: Foster City
- State: CA
- Country: United States
- Sector: Health Care
- Foundation year: 1987
- Industry: Pharmaceuticals
- CEO: Daniel P. O'Day
- Stack: Google Analytics
Latest news (see all)
CymaBay shares jumped nearly 25% to hit a record after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead for $4.3 billion.
Read: The Wall Street Journal
2024-02-13
CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal
Read: The Wall Street Journal
2024-02-12
CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal
Read: The Wall Street Journal
2024-02-12
Stocks making the biggest moves midday: Vita Coco, Archer-Daniels-Midland, Gilead Sciences and more
Read: CNBC News
2024-01-22
Stocks making the biggest moves midday: Amazon, Lennar, GoodRx, Gilead Sciences and more
Read: CNBC News
2024-01-10
Metrics
General information
Business
| assets | 68B $ |
| Debt | 26.2B $ |
| free cash flow | 8,696,380,000.00 |
| market cap | 80,337,200,000.00 |
| profits | 6.2B $ |
Visualizations
Datasets
rows
Companies in the United States
rows
Companies where Industry equals Pharmaceuticals
rows
Companies where Sector equals Health Care
rows
Stocks for Gilead Sciences
Source
Updated: 3 days ago
